Flumadine | The Medical Letter Inc.

Matching articles for "Flumadine"

Antiviral Drugs for Seasonal Influenza 2014-2015

The Medical Letter on Drugs and Therapeutics • December 8, 2014; (Issue 1457)

Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is available...

Med Lett Drugs Ther. 2014 Dec 8;56(1457):121-2 | Show Full Introduction Hide Full Introduction

Antiviral Drugs

The Medical Letter on Drugs and Therapeutics • March 1, 2013; (Issue 127)

The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.

Treat Guidel Med Lett. 2013 Mar;11(127):19-30 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza 2012-2013

The Medical Letter on Drugs and Therapeutics • December 10, 2012; (Issue 1405)

Antiviral drugs can be used as an adjunct to vaccination for prophylaxis and treatment of influenza. In recent years, the susceptibility of circulating influenza virus strains has evolved rapidly and treatment recommendations have changed during the influenza season. Frequently updated information on antiviral resistance is available at www.cdc.gov/flu/professionals/antivirals.

Med Lett Drugs Ther. 2012 Dec 10;54(1405):97-8 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza

The Medical Letter on Drugs and Therapeutics • January 9, 2012; (Issue 1381)

Antiviral drugs can be used for treatment and prophylaxis of influenza. In recent years, the susceptibility of circulating influenza strains has evolved rapidly and treatment recommendations have changed during the influenza season. The CDC influenza website provides frequently updated information on antiviral resistance (www.cdc.gov/flu).

Med Lett Drugs Ther. 2012 Jan 9;54(1381):1-3 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza

The Medical Letter on Drugs and Therapeutics • January 10, 2011; (Issue 1355)

Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis when exposure to the disease occurs before or less than 2 weeks after vaccination. They can also be used to control institutional outbreaks of influenza. In recent years, the susceptibility of circulating influenza strains has evolved rapidly and treatment recommendations have changed during the influenza season. The CDC influenza web site provides frequently updated information on antiviral resistance (www.cdc.gov/flu)

Med Lett Drugs Ther. 2011 Jan 10;53(1355):1-3 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • October 1, 2010; (Issue 98)

The drugs of choice for treatment of non-HIV viral infections and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed in another issue of Treatment Guidelines.

Treat Guidel Med Lett. 2010 Oct;8(98):71-82 | Show Full Introduction Hide Full Introduction

Drugs Past Their Expiration Date

The Medical Letter on Drugs and Therapeutics • December 14, 2009; (Issue 1327)

Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might not even comment on the safety or effectiveness of using their products beyond the date on the label. Since the last Medical Letter publication on this subject, more data have become available.

Med Lett Drugs Ther. 2009 Dec 14;51(1327):100-1 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza

The Medical Letter on Drugs and Therapeutics • November 16, 2009; (Issue 1325)

Currently circulating influenza virus is almost universally pandemic 2009 influenza A H1N1, but seasonal influenza strains could also appear soon. Antiviral drugs are an important adjunct to influenza vaccination for treatment and chemoprophylaxis of both pandemic and seasonal influenza. They may, however, interfere with the efficacy of FluMist, the live-attenuated intranasal vaccine, if they are administered within 48 hours before or <2 weeks after FluMist administration. Inactivated vaccines are not affected by antiviral drug therapy.

Med Lett Drugs Ther. 2009 Nov 16;51(1325):89-92 | Show Full Introduction Hide Full Introduction

More Resistance to Oseltamivir (Tamiflu)

The Medical Letter on Drugs and Therapeutics • January 26, 2009; (Issue 1304)

Since publication of our recent article on antiviral drugs for influenza, increased levels of resistance to oseltamivir (Tamiflu) have been detected in influenza A H1N1...

Since publication of our recent article on antiviral drugs for influenza, increased levels of resistance to oseltamivir (Tamiflu) have been detected in influenza A H1N1 strains.

Med Lett Drugs Ther. 2009 Jan 26;51(1304):5-6 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza

The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)

Antiviral drugs are an important adjunct to influenza vaccination and can be used for treatment of patients with influenza within 2 days of the onset of illness and for chemoprophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. Patients who are immunocompromised or immunosuppressed, have pulmonary disease, are elderly or are healthcare workers may also be appropriate candidates for chemoprophylaxis.

Med Lett Drugs Ther. 2008 Dec 15;50(1301):98-9 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Influenza

The Medical Letter on Drugs and Therapeutics • October 22, 2007; (Issue 1272)

Antiviral drugs can be used for treatment of patients with influenza and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination. They can also be used to control institutional influenza outbreaks and for prophylaxis in years when circulating strains differ from those included in the vaccine.

Med Lett Drugs Ther. 2007 Oct 22;49(1272):85-6 | Show Full Introduction Hide Full Introduction

Drugs for Parkinson's Disease

The Medical Letter on Drugs and Therapeutics • October 1, 2007; (Issue 62)

ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the...

Treat Guidel Med Lett. 2007 Oct;5(62):89-94 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • July 1, 2007; (Issue 59)

The drugs of choice for treatment of non-HIV viral infections with their dosages and cost are listed in Tables 1-6. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used in the prevention of viral infections are discussed in the "Adult Immunization" issue of Treatment Guidelines.

Treat Guidel Med Lett. 2007 Jul;5(59):59-70 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Prophylaxis and Treatment of Influenza

The Medical Letter on Drugs and Therapeutics • October 23, 2006; (Issue 1246)

Antiviral drugs can be used to control institutional influenza outbreaks and for prophylaxis of influenza exposures that occur before or less than 2 weeks after vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. They can also be used for early treatment of patients with influenza.

Med Lett Drugs Ther. 2006 Oct 23;48(1246):87-8 | Show Full Introduction Hide Full Introduction

Update: Influenza Resistance to Amantadine and Rimantadine

The Medical Letter on Drugs and Therapeutics • January 30, 2006; (Issue 1227)

Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005;47:93) mentioned possible use of amantadine (Symmetrel, and others) and rimantadine (Flumadine, and others),...

Our article on Antiviral Drugs for Prophylaxis and Treatment of Influenza (Med Lett Drugs Ther 2005;47:93) mentioned possible use of amantadine (Symmetrel, and others) and rimantadine (Flumadine, and others), but warned that the incidence of resistance has increased substantially. The CDC recently issued a Health Alert (www.cdc.gov) saying that current evidence indicates that a high proportion of circulating influenza A viruses in the US are now resistant to amantadine and rimantadine and they should not be used for this indication, at least this year. Click here to go to this update article.

Med Lett Drugs Ther. 2006 Jan 30;48(1227):12 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Prophylaxis and Treatment of Influenza

The Medical Letter on Drugs and Therapeutics • November 21, 2005; (Issue 1222)

Antiviral prophylaxis is indicated for influenza exposures that occur before (or less than 2 weeks after) vaccination with inactivated vaccine, or in years when circulating strains differ from those included in the vaccine. Antiviral drugs can also be used for treatment of patients who develop symptoms of influenza, regardless of vaccination status.
Please see Update: Influenza Resistance to Amantadine and Rimantadine

Med Lett Drugs Ther. 2005 Nov 21;47(1222):93-5 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • April 1, 2005; (Issue 32)

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the tables that begin on page 24. Some of the indications and dosages recommended here have not been approved by the...

Treat Guidel Med Lett. 2005 Apr;3(32):23-32 | Show Full Introduction Hide Full Introduction

Antiviral Drugs for Prophylaxis and Treatment of Influenza

The Medical Letter on Drugs and Therapeutics • October 25, 2004; (Issue 1194)

Due to the unanticipated shortage in the US supply of inactivated influenza vaccine, many persons who normally would have received the vaccine will be unable to get it this year. Antiviral drugs can be used for prophylaxis of unvaccinated persons who are exposed to influenza, and for treatment of both vaccinated and unvaccinated patients who develop symptoms of the disease.

Med Lett Drugs Ther. 2004 Oct 25;46(1194):85-7 | Show Full Introduction Hide Full Introduction

Drugs for Parkinson's Disease

The Medical Letter on Drugs and Therapeutics • June 1, 2004; (Issue 22)

Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the...

Treat Guidel Med Lett. 2004 Jun;2(22):41-6 | Show Full Introduction Hide Full Introduction

Influenza Prevention 2003-2004

The Medical Letter on Drugs and Therapeutics • September 29, 2003; (Issue 1166)

Unlike the last few years there is no early-season shortage of influenza vaccine. Immunization programs for all recommended individuals can proceed. There are 2 new influenza vaccine formulations available this year, FluMist, an intranasal vaccine and Fluzone, a pediatric formulation. Timing, indications, adverse effects, dosage and cost of the vaccines is discussed. The drugs that can be used for prophylaxis of influenza are also reviewed.

Med Lett Drugs Ther. 2003 Sep 29;45(1166):78-80 | Show Full Introduction Hide Full Introduction

Drugs for Pneumonia

The Medical Letter on Drugs and Therapeutics • September 1, 2003; (Issue 13)

The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.

Treat Guidel Med Lett. 2003 Sep;1(13):83-8 | Show Full Introduction Hide Full Introduction

FluMist: An Intranasal Live Influenza Vaccine

The Medical Letter on Drugs and Therapeutics • August 19, 2003; (Issue 1163)

FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray,...

FluMist (MedImmune), the first live-attenuated and first intranasally administered influenza vaccine, has been approved by the FDA to prevent influenza in healthy people 5-49 years old. Given as a nasal spray, it stimulates immunity by viral replication in the upper respiratory tract. This vaccine apparently will be advertised directly to the public as a "needle-free" alternative to intramuscular influenza vaccine.

Med Lett Drugs Ther. 2003 Aug 19;45(1163):65-6 | Show Full Introduction Hide Full Introduction

Influenza Prevention 2002-2003

The Medical Letter on Drugs and Therapeutics • September 2, 2002; (Issue 1138)

Influenza vaccine for the 2002-2003 season will include last year's A strains, A/New Caledonia/20/99 (H1N1)-like and A/Moscow/10/99 (H3N2)-like, and a new B strain, B/Hong-Kong/330/01-like (MMWR Morb Mortal...

Med Lett Drugs Ther. 2002 Sep 2;44(1138):75-6 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • February 4, 2002; (Issue 1123)

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table that begins on the next page. Since the last Medical Letter issue on this subject, some new drugs and some...

Med Lett Drugs Ther. 2002 Feb 4;44(1123):9-16 | Show Full Introduction Hide Full Introduction

Influenza Prevention 2001-2002

The Medical Letter on Drugs and Therapeutics • September 17, 2001; (Issue 1113)

The centers for Disease Control and Prevention is anticipating a delay, but not a shortage, of influenza vaccine for the 2001-2002 season. Last year manufacturing problems led to a substantial delay in vaccine availability. This year's delay is being attributed, in part, to the dicontinuation of the Fluogen (King) brand of vaccine. The 2001-02 vaccine will include A/New Caledonia/20/99 (H1N1)-like, A/Moscow/10/99 (H3N2)-like, and B/Sichuan/379/99-like antigens.

Med Lett Drugs Ther. 2001 Sep 17;43(1113):81-2 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • December 3, 1999; (Issue 1067)

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's]...

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the [article's] table.

Med Lett Drugs Ther. 1999 Dec 3;41(1067):113-20 | Show Full Introduction Hide Full Introduction

Two Neuraminidase Inhibitors for Treatment of Influenza

The Medical Letter on Drugs and Therapeutics • October 8, 1999; (Issue 1063)

Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved...

Zanamivir, a neuraminidase inhibitor taken by inhalation, has been approved by the FDA for treatment of influenza. Oseltamivir phosphate, an oral neuraminidase inhibitor, will probably be approved soon.

Med Lett Drugs Ther. 1999 Oct 8;41(1063):91-3 | Show Full Introduction Hide Full Introduction

Drugs for Non-HIV Viral Infections

The Medical Letter on Drugs and Therapeutics • August 1, 1997; (Issue 1006)

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future...

The drugs of choice for non-HIV viral infections with their dosages and cost are listed in the table on the next page. The treatment of HIV infection will be discussed in a future issue.

Med Lett Drugs Ther. 1997 Aug 1;39(1006):69-76 | Show Full Introduction Hide Full Introduction

Rimantadine for Prevention and Treatment of Influenza

The Medical Letter on Drugs and Therapeutics • November 26, 1993; (Issue 910)

Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of...

Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.

Med Lett Drugs Ther. 1993 Nov 26;35(910):109-10 | Show Full Introduction Hide Full Introduction

Drugs for Viral Infections

The Medical Letter on Drugs and Therapeutics • August 10, 1990; (Issue 824)

...

Med Lett Drugs Ther. 1990 Aug 10;32(824):73-8 | Show Full Introduction Hide Full Introduction